MD Anderson Cancer Center and Lion Biotechnologies Inc, a biotechnology company developing cancer immunotherapies based on tumor-infiltrating lymphocyte technology, announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
